Stock Analysis on Net
Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity 

Abiomed Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Accounts payable 2.11 2.33 2.69 3.05 3.00 3.75
Employee compensation 3.03 2.74 2.65 3.12 3.86 4.23
Research and development 0.44 0.47 0.47 0.31 0.40 0.43
Marketing 0.14 0.25 0.14 0.16 0.29 0.33
Warranty 0.12 0.14 0.15 0.12 0.14 0.13
Sales and income taxes 0.12 0.40 1.78 1.16 0.58 0.58
Professional, legal and accounting fees 0.09 0.13 0.57 0.26 0.24 0.37
Other 0.42 0.30 0.41 0.30 0.36 0.79
Accrued expenses 4.34% 4.42% 6.17% 5.45% 5.87% 6.85%
Deferred revenue 1.58 1.63 1.57 1.55 1.90 1.91
Other current liabilities 0.25 0.25 0.40 0.00 0.00 0.00
Current portion of capital lease obligation 0.00 0.00 0.00 0.00 0.00 0.15
Current liabilities 8.27% 8.63% 10.84% 10.05% 10.77% 12.65%
Other long-term liabilities 0.56 0.68 0.76 0.10 0.10 0.59
Contingent consideration 1.29 1.65 0.74 0.91 1.33 1.66
Deferred tax liabilities 0.05 0.06 0.07 0.08 0.11 0.14
Capital lease obligation, net of current portion 0.00 0.00 0.00 0.00 0.00 2.82
Long-term liabilities 1.89% 2.39% 1.57% 1.09% 1.55% 5.22%
Total liabilities 10.16% 11.02% 12.41% 11.14% 12.32% 17.87%
Class B Preferred Stock, $.01 par value; none issued and outstanding 0.00 0.00 0.00 0.00 0.00 0.00
Common stock, $.01 par value 0.03 0.03 0.04 0.04 0.06 0.08
Additional paid in capital 51.99 53.58 60.76 65.49 78.83 102.82
Retained earnings (accumulated deficit) 57.64 55.41 49.53 37.89 17.86 -8.53
Treasury stock at cost -18.20 -19.27 -21.82 -13.17 -8.53 -8.50
Accumulated other comprehensive loss -1.62 -0.77 -0.92 -1.39 -0.53 -3.74
Stockholders’ equity 89.84% 88.98% 87.59% 88.86% 87.68% 82.13%
Total liabilities and stockholders’ equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Abiomed Inc. current liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2020 to 2021 and from 2021 to 2022.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Abiomed Inc. long-term liabilities as a percentage of total liabilities and stockholders’ equity increased from 2020 to 2021 but then slightly decreased from 2021 to 2022 not reaching 2020 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Abiomed Inc. total liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2020 to 2021 and from 2021 to 2022.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Abiomed Inc. stockholders’ equity as a percentage of total liabilities and stockholders’ equity increased from 2020 to 2021 and from 2021 to 2022.